Medicover Hospitals, Navi Mumbai Organizes Free Screening Camp on World Liver Day

· A large number of people in the country are suffering from Nonalcoholic fatty liver disease (NAFLD) leading to cirrhosis and ultimately liver transplant or even death

·  Timely detection of liver ailments through regular screening is key in diagnosing and managing liver problems

 To mark the occasion of World Liver Day, Medicover Hospitals, Navi Mumbai conducted a free liver screening camp for people in Maharashtra. The camp was organised  at Medicover Hospitals Mumbai, Pune, Nashik, Chhatrapati SambhajiNagar and Sangamner. The screening program was  launched by Dr Amritraj C., Dr Hirak Pahari, Dr Naveen KN, Dr Vikram Raut, Mr Jashanjeet and Mr Durgaprasad. More than 10,000 people will be screened with the Complimentary Liver Screening package which includes liver function tests, USG abdomen, medical/Surgical Gastroenterologist consultation from 19th April to 31st May.

Currently, liver ailments are commonly seen in people of all age groups. A large number of people are getting detected with non-alcoholic fatty liver disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), end-stage chronic liver disease, cirrhosis, liver failure, acute and chronic hepatitis, liver cancer, bile duct cancer. But, NAFLD is a common problem seen in people nowadays. It is the need of the hour to provide appropriate treatment to patients with the help of various screening tools. Medicover Hospitals, Navi Mumbai has now come forward and organized a screening camp to aid in early detection and save lives.

Dr Vikram Raut, Director- Liver transplantation and HPB surgery, Medicover Hospitals, Navi Mumbai said, “Non-alcoholic fatty liver disease (NAFLD) is becoming a frequent liver disease in those having metabolic syndrome. Recent studies show 30% of the population in India is suffering from NAFLD. Complications of NAFLD are fibrosis, cirrhosis, and hepatocellular carcinoma. NAFLD also leads to cardiovascular disease, extrahepatic neoplasia, and other organ damage, such as renal insufficiency.  NAFLD is regarded as one component of metabolic syndrome, including obesity, insulin resistance or type 2 diabetes mellitus (T2DM), hypertension, and dyslipidemia. NAFLD patients at different stages of the disease suffer from Non-alcoholic steatohepatitis (NASH) and cirrhosis. Over the next decade, the number of patients with advanced fibrosis stages is expected to surge. The number of NASH patients with advanced fibrosis is expected to more than double by 2030.”

Dr Vikram Raut added, “To help people deal with NAFLD and other liver problems, we came up with a free screening camp wherein people were closely monitored to determine treatment for them. We performed the abdominal US as the initial examination to determine the presence of steatosis. Serum fibrosis tests were done for further risk stratification. Those having diabetes with high HbA, obesity, hypertension, and dyslipidemia were screened in the camp as such people are at a greater risk of suffering from liver problems.